GPEx® Lightning: Achieving Rapid, High-Titer Expression For Next-Generation Biologics

Join this webinar for insights into how advanced cell line engineering accelerates production timelines for multispecific antibodies and complex protein therapeutics. This presentation examines a proprietary platform that integrates targeted genomic integration with tunable expression controls, enabling balanced multi-chain assembly in challenging formats including bispecifics, Fc fusions, and recombinant proteins. Discover how strategic gene copy number modulation addresses persistent challenges in next-generation biologics: maintaining consistent quality across generations, achieving proper chain pairing in multi-component molecules, and delivering commercial-scale titers without extensive optimization.

Multiple case studies demonstrate performance across diverse molecular architectures, from VHH-Fc fusions to four-chain bispecifics, with productivity consistently reaching 3-15 grams per liter using platform processes. Learn how the integrated approach of spanning stable pool creation through GMP manufacturing reduces development timelines while supporting innovation in therapeutic formats that demand precise stoichiometric expression.

Tune in below for more information on strategies for balancing titer with protein quality, addressing aggregation in complex assemblies, and accelerating the path from molecule to market for your next-generation biologics programs.